Our mass spectrometric approach further allowed us to validate P(BCMA)B*18 additionally as a target for CLL, for which plasma BCMA-levels were described as a prognostic factor34. This evidence concerns the gene TNFRSF17 and B-cell chronic lymphocytic leukemia.